On March 17, 2023, Stifel initiated coverage of Viking Therapeutics with a Buy recommendation.
Analyst Price Forecast Suggests 79.22% Upside
As of March 17, 2023, the average one-year price target for Viking Therapeutics is $19.61. The forecasts range from a low of $12.12 to a high of $31.50. The average price target represents an increase of 79.22% from its latest reported closing price of $10.94.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Viking Therapeutics is $0MM. The projected annual non-GAAP EPS is -$1.01.
What are Large Shareholders Doing?
Millennium Management holds 4,382K shares representing 5.59% ownership of the company. In it's prior filing, the firm reported owning 3,103K shares, representing an increase of 29.19%. The firm increased its portfolio allocation in VKTX by 356.66% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,231K shares representing 2.85% ownership of the company. No change in the last quarter.
Boxer Capital holds 1,500K shares representing 1.91% ownership of the company. In it's prior filing, the firm reported owning 0K shares, representing an increase of 100.00%.
Laurion Capital Management holds 1,299K shares representing 1.66% ownership of the company. No change in the last quarter.
Great Point Partners holds 1,295K shares representing 1.65% ownership of the company.
What is the Fund Sentiment?
There are 184 funds or institutions reporting positions in Viking Therapeutics. This is a decrease of 5 owner(s) or 2.65% in the last quarter. Average portfolio weight of all funds dedicated to VKTX is 0.08%, an increase of 365.99%. Total shares owned by institutions increased in the last three months by 26.65% to 35,130K shares. The put/call ratio of VKTX is 0.16, indicating a bullish outlook.
Viking Therapeutics Background Information
(This description is provided by the company.)
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1 first-in-human clinical trial. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
